| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.76 [0.56, 1.04] | | < 1 | | 73% | 2 studies (2/-) | 95.6 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.64 [0.51, 0.80] | | < 1 | | 63% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DOR | 2.14 [1.13, 4.04] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.76 [1.14, 2.70] | | > 1 | | 72% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.29 [0.55, 9.43] | | < 1 | | 54% | 2 studies (2/-) | 12.7 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.17 [0.85, 1.60] | | < 1 | | 44% | 2 studies (2/-) | 17.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.84 [0.95, 3.59] | | < 1 | | 54% | 2 studies (2/-) | 3.6 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.17 [1.63, 2.88] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.09 [1.28, 3.39] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 2.28 [1.66, 3.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 2.27 [1.46, 3.51] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.80 [0.98, 3.28] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.57 [1.14, 2.15] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.58 [0.68, 3.68] | | < 1 | | 0% | 2 studies (2/-) | 14.6 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.09 [0.76, 1.58] | | < 1 | | 0% | 1 study (1/-) | 31.9 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.77 [0.28, 2.10] | | < 1 | | 0% | 1 study (1/-) | 69.3 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 8.08 [0.43, 153.53] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.50 [0.02, 14.93] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 3.41 [0.93, 12.49] | | < 1 | | 0% | 1 study (1/-) | 3.3 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 6.05 [0.30, 121.16] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.44 [0.54, 3.83] | | < 1 | | 0% | 1 study (1/-) | 23.2 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.89 [0.75, 4.80] | | < 1 | | 0% | 1 study (1/-) | 9.0 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 2.66 [1.10, 6.46] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.00 [0.06, 16.05] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 4.02 [0.18, 89.44] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.46 [0.72, 2.93] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 3.55 [0.73, 17.23] | | < 1 | | 0% | 1 study (1/-) | 5.8 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.93 [0.65, 1.35] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 2.01 [0.37, 11.06] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 4.04 [0.45, 36.31] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.68 [0.40, 7.07] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.01 [0.18, 22.23] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.16 [0.68, 2.00] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 3.02 [0.31, 29.16] | | < 1 | | 0% | 1 study (1/-) | 17.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 10.24 [0.56, 188.30] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.33 [0.03, 3.22] | | < 1 | | 0% | 1 study (1/-) | 82.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.72 [0.46, 1.11] | | < 1 | | 0% | 1 study (1/-) | 93.3 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 2.03 [0.37, 11.17] | | < 1 | | 0% | 1 study (1/-) | 20.9 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.60 [0.21, 1.66] | | < 1 | | 0% | 1 study (1/-) | 83.9 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 2.04 [0.50, 8.23] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.67 [0.11, 4.04] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.67 [0.11, 4.04] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.21 [0.37, 4.02] | | < 1 | | 0% | 1 study (1/-) | 37.6 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.88 [0.69, 5.16] | | < 1 | | 0% | 1 study (1/-) | 11.0 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 3.04 [0.31, 29.44] | | < 1 | | 0% | 1 study (1/-) | 17.0 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 1.01 [0.02, 50.94] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.82 [0.33, 2.01] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 2.02 [0.07, 60.40] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Hypophysitis AE (grade 3-4) | 4.05 [0.18, 90.23] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 2.02 [0.07, 60.40] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 4.07 [0.45, 36.67] | | < 1 | | 0% | 1 study (1/-) | 10.7 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 2.02 [0.18, 22.43] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.75 [0.17, 3.39] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.90 [0.61, 1.32] | | < 1 | | 0% | 1 study (1/-) | 70.9 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 1.52 [0.25, 9.15] | | < 1 | | 0% | 1 study (1/-) | 32.6 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 3.07 [0.61, 15.32] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.01 [0.14, 7.20] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Severe skin reactions AE (grade 3-4) | 3.04 [0.31, 29.44] | | < 1 | | 0% | 1 study (1/-) | 17.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.07 [0.55, 2.08] | | < 1 | | 0% | 1 study (1/-) | 42.4 % | NA | not evaluable | | non important | - |
| Thyroiditis AE (grade 3-4) | 2.02 [0.07, 60.40] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.16 [0.02, 1.38] | | < 1 | | 0% | 1 study (1/-) | 95.1 % | NA | not evaluable | | non important | - |
